Improved fibrosis staging by elastometry and blood test in chronic hepatitis C

Area of Science:

• Hepatology
• Medical Diagnostics
• Biomarker Discovery

Background:

• Non-invasive fibrosis staging is crucial for managing chronic liver diseases.
• Previous methods like FibroMeter and FibroScan have limitations in accuracy and precision.
• There is a need for improved diagnostic tools to accurately stage liver fibrosis.

Purpose of the Study:

• To enhance non-invasive liver fibrosis staging accuracy by combining multiple diagnostic tests.
• To develop a more precise fibrosis classification system.
• To improve the reliability and personalized accuracy of fibrosis staging.

Main Methods:

• A derivation population of 729 patients with chronic hepatitis C underwent liver biopsy, six blood tests, and FibroScan.
• Validation was performed on an additional 1584 patients.
• A novel combination, 'E-FibroMeter', integrating FibroMeter markers and FibroScan results was developed.

Main Results:

• E-FibroMeter achieved 91.7% classification accuracy, outperforming FibroMeter (84.1%) and FibroScan (88.2%).
• Accuracy for detecting absence of fibrosis (F0) increased from 16.0% (FibroScan) to 75.0% (E-FibroMeter).
• Cirrhosis sensitivity improved to 92.7% with E-FibroMeter, compared to 83.3% with FibroScan, and reliability increased to 94.2%.

Conclusions:

• The E-FibroMeter combination significantly improves liver fibrosis staging accuracy, precision, and reliability.
• This novel approach enhances the detection of fibrosis absence and improves cirrhosis prediction.
• E-FibroMeter offers a more accurate and dependable non-invasive tool for liver fibrosis assessment.